Drug intelligence / Profile preview

Huage granules

Development stage: Unknown
Lead developer: Henan Cancer Hospital
Administration: Oral

Overview

Huage granules is a Traditional Chinese Medicine (TCM) formulation developed by Henan Cancer Hospital. It is designed based on the therapeutic principle of 'benefiting qi and resolving blood stasis' (Yi Qi Hua Yu) to address the underlying pathology of esophageal squamous cell carcinoma (ESCC) in the postoperative phase. The drug is intended to prevent tumor recurrence and metastasis by modulating the body's internal environment and potentially inhibiting residual cancer cell activity. It is currently being evaluated in multicenter randomized controlled clinical trials to establish high-level evidence for its efficacy and safety in the rehabilitation of esophageal cancer patients.

Brand names: Huage granules
Other names: Huage

Beyond the preview

Go deeper on Huage granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huage granules.

Explore the full profile